ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023
April 18, 2023 09:00 ET
|
ImCheck Therapeutics SAS
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023 ICT01 in combination with low dose IL-2 safely...
ImCheck Appoints Thomas Civik as Independent Chairman of the Board
March 23, 2023 03:00 ET
|
ImCheck Therapeutics SAS
ImCheck Appoints Thomas Civik as Independent Chairman of the Board Marseille, France, March 23, 2023 – ImCheck Therapeutics announced today the appointment of Thomas Civik as independent...
ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR
March 14, 2023 17:30 ET
|
ImCheck Therapeutics SAS
ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR Marseille, France, March 14, 2023 – ImCheck Therapeutics...
ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting
November 11, 2022 10:12 ET
|
ImCheck Therapeutics SAS
Low-dose ICT01 plus low-dose IL-2 safely and significantly increase the number of activated γ9δ2 T cells, CD8 T cells, and Natural Killer cells in patients with solid tumors Marseille, France,...
Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at ESMO Congress 2022
September 10, 2022 09:15 ET
|
ImCheck Therapeutics SAS
Broad antitumor immune responses and demonstration of durable disease control from solid tumor patients who previously failed one or more checkpoint-inhibitor regimen, across a range of ICT01 doses in...
ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline
June 13, 2022 01:00 ET
|
ImCheck Therapeutics SAS
Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, to completion of randomized Phase II trialsSeries C adds global investors Earlybird, Andera...
ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022
April 08, 2022 13:00 ET
|
ImCheck Therapeutics SAS
ImCheck Provides Updated ICT01 and Pembrolizumab Combination Datafrom the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022 Continued positive safety data across a range of ICT01 doses...
ImCheck Announces First Patients Dosed in Phase II of EVICTION Trial for ICT01
February 03, 2022 05:03 ET
|
ImCheck Therapeutics SAS
ImCheck Announces First Patients Dosedin Phase II of EVICTION Trial for ICT01 EVICTION trial proceeds to Phase IIa based on promising Phase I patient datafor ICT01 across a broad range of...
ImCheck to Present at 40th Annual J.P. Morgan Healthcare Conference
January 06, 2022 06:00 ET
|
ImCheck Therapeutics SAS
ImCheck to Present at 40th Annual J.P. Morgan Healthcare Conference Marseille, France, January 6, 2022 – ImCheck Therapeutics announced today that its Chief Executive Officer, Pierre...
ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021
November 12, 2021 14:20 ET
|
ImCheck Therapeutics SAS
Oral presentation includes positive safety data across a wide range of ICT01 doses and efficacy data from patients receiving ICT01 plus pembrolizumab confirming durable clinical responses at low ICT01...